Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity.
Grob
C
C
Bravo
G
G
Walsh
R
R
D015104:3,4-Methylenedioxyamphetamine / Q000031:analogs & derivatives / Q000627:therapeutic use / Q000633:toxicity*; D000662:Amphetamines / Q000633:toxicity*; D000818:Animals; D002986:Clinical Trials as Topic; D015198:Designer Drugs / Q000633:toxicity*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D009422:Nervous System Diseases / Q000139:chemically induced*; D051381:Rats; D012107:Research Design / Q000592:standards; D019966:Substance-Related Disorders / Q000150:complications
D000662:Amphetamines; D015198:Designer Drugs; D015104:3,4-Methylenedioxyamphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine